250
Views
2
CrossRef citations to date
0
Altmetric
Commentaries

Effectiveness of the new inflammatory parameters in patients with chronic spontaneous urticaria

Page 71 | Received 10 Nov 2019, Accepted 22 Nov 2019, Published online: 06 Dec 2019
 

Abstract

In recent years, neutrophil-lymphocyte ratio and platelet-lymphocyte ratio have been studied in many dermatological diseases as various parameters indicating inflammation, and found to be associated with disease activity, prognosis and spread of disease 2,3. In the present study, authors found a significant decrease in the neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and C-Reactive Protein after omalizumab treatment. However, a limited number of patients had C-Reactive Protein levels. Since no correlation analysis was performed in the study, the significance of these results remains weak. Moreover, it was not specified whether there were any other drugs used by the patients. In spontaneous urticaria, disease activity is assessed by a robust and simple scoring system named as Urticaria Activity Score 4. In the present study, Urticaria Activity Score was not mentioned, and no information was given about the severity of the disease in these population. The post-treatment change in Urticaria Activity Score will be more valuable for both to evaluate the response to treatment and to demonstrate the usefulness of these parameters. Future studies should focus on randomized trials with more detailed information, with greater emphasis on clinical endpoints.

Disclosure statement

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.